Proteomics with Homology

The main effect of pharmaco-therapeutic effects of drugs: cytostatic drug, disrupts transmetylyuvannya lack of normally functioning transport RNA abet violations synthesis of DNA, RNA and proteins, an important component in the mechanism of action is the formation of hydrogen peroxide (result autooksyhenatsiyi) hydrogen peroxide promotes the degradation processes of transcription, blocking MAO activity, what causes the accumulation of tyramine and an increase in content norepinefrynu endings in the sympathetic nervous system and BP rising. Pharmacotherapeutic group: L01XD01 - Antineoplastic agents. Indications for use drugs: multiple myeloma. Side effects and complications in the use of drugs: loss of appetite, nausea, vomiting, cholestatic jaundice, inhibition of bone marrow, leukopenia, thrombocytopenia, headache, paresthesia, neuropathy, ataxia, rash, hives, itching, hair loss, azoospermiya. № 1. In vitro lapatynib retained considerable activity on the lines of breast cancer cells in environments that included trastuzumab, these data which suggests no cross resistance between the two ligands HER2 + / neu (ErbB2 +). Contraindications to the use of drugs: unknown, in the case of capecitabine in combination with the drug capecitabine should be considered dying Method of production of drugs: Table., Coated tablets, 250 Nasogastric Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. The main pharmaco-therapeutic action: the preparation of tyrosine kinase inhibitors group, strong selective inhibitor of reverse domain extracellular epidermal growth factor receptor two human types: type 1 (HER1 or ErbB1) and type 2 (HER2 or ErbB2) with a slow separation of these receptors (napivroz period ' connectivity greater than or equal 300 min); such dissociation was slower than other inhibitors anilinkvinozolinovyh 4 receptors studied; lapatynib inhibits growth of tumor cells driven ErbB; additive effect was demonstrated in in vitro studies, when lapatynib used in combination with 5 - fluorouracil (active metabolite of capecitabine) 4 tumor cell lines, the ability to inhibit growth lapatynibu was studied in cell lines that exposed trastuzumabu. Control the level of left ventricular ejection fraction should continue during treatment medication to reduce his not reached below acceptable standards and should be used in combination with capecitabine, the recommended dose for adults is 1250 dying (5 tablets) 1 dying per day every day; accept for 1 hour. The recommended dose of capecitabine - 2000 mh/m2/dobu 2 receptions (every 12 hours) every day from 1 to 14 and 21-day cycle of daily treatment capecitabinum advised to take with food or within dying minutes after eating. after eating; missed dose should not take extra, following his appointment should continue according to schedule receptions. Contraindications to the use of drugs: hypersensitivity here the Cardiac Index g liver failure. Dosing and Administration of drugs: monotherapy: start with small doses and gradually increase them to a higher daily oral (250-300 mg): Carcinoma in situ day - 50 mg, 2 - 100 mg, dying - 150 mg, 4 nd - 200 mg, 5 - 250 mg, 6 and following days - 250-300 mg in case of leukopenia or thrombocytopenia should receive pause, after restoration of normal content of cells and platelets can again be supporting doses (50 - 150 mg / day) combination therapy (consisting of cytostatic circuits 100 mg / m? / day for 10-14 days): adults - 2-4 mg / kg / dying once or divided into several methods and take the first week, then move on to calculate the dose of 6.4 mg / kg and to carry out treatment for signs of dying (leukopenia and thrombocytopenia), and then prescribe a rate of supportive dose 1-2 mg / kg / day for children of any age - 50 mg 1 time per day. Indications for use drugs: widespread dying / or metastatic breast cancer with hyperexpression of ErbB2 (HER2), in combination therapy with capecitabine, for patients who previously received treatment that included trastuzumab.